4D Molecular Therapeutics (FDMT) PT Lowered to $63 at BMO Capital, 'uncertainty remains a lingering overhang until the PhIII readout'
Tweet Send to a Friend
(Updated - March 28, 2024 1:32 PM EDT)
BMO Capital analyst Kostas Biliouris lowered the price target on 4D ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
BMO Capital analyst Kostas Biliouris lowered the price target on 4D ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
